Key points from article :
Attovia Therapeutics, a biotherapeutics company, has been launched with a $60 million Series A funding round, led by Frazier Life Sciences and featuring venBio and Illumina Ventures as investors.
The new company, formed in partnership with Alamar Biosciences, holds a global exclusive license for Alamar's biparatopic nanobody platform, Attobody.
The funding will be used to achieve clinical proof-of-concept on the company's leading program in immune-mediated diseases and to identify additional development candidates in immunology and oncology.
The Attobody platform creates small format binders known as "Attobodies," which are effective in binding with hard-to-drug targets like G-protein-coupled receptors (GPCRs).
Tao Fu, a venture partner at Frazier Life Sciences, will take up the role of CEO at Attovia, with Dr. Jamie Topper and Dr. Aaron Royston from Frazier and venBio, respectively, joining Attovia’s Board of Directors.
The companies believe in Attovia's potential to create a robust pipeline of first- and best-in-class drugs using the Attobody platform.
